Insulin Patch Pump Systems Sustained Glucose Control
A large-scale analysis of adults with type 1 diabetes found consistent glucose management using a micro-dosing pump.
Updated on Oct. 1, 2026 in Diabetes
Live Poll
Do you believe automated health monitoring technology improves daily life for patients with chronic conditions?
Researchers presented findings on the real-world performance of the Kaleido insulin patch pump system, which showed stable glucose control in nearly 4,000 adults with type 1 diabetes. The data confirms how the device functions for users across Germany, the Netherlands, and France.
Why it matters
Real-world evidence helps bridge the gap between controlled clinical trials and actual daily use, showing how automated insulin delivery systems perform in varied settings. This information assists patients and clinicians in evaluating the reliability of automated systems for long-term glucose management.
This real-world analysis tracked 3,918 adults over 323,814 person-days of device usage. Participants maintained a median time in range of 72.2% and a low median time below 54 mg/dL of 0.21%, though these figures represent observational performance rather than a randomized trial.
The players
ViCentra
A developer of insulin delivery technologies headquartered in the Netherlands that specializes in patch pump systems.
Diabeloop
A developer of automated insulin delivery algorithms designed to simplify diabetes management.
Dexcom
A manufacturer of continuous glucose monitoring technology widely used to track real-time blood sugar levels.
The details
The Kaleido system uses a valved micro-dosing mechanism with two one-way valves, replacing the traditional syringe-driven delivery method. The system integrates the Dexcom G6 continuous glucose monitor with the DBLG1 automated insulin delivery algorithm from Diabeloop, which allows the device to operate in a closed-loop mode for 97% of sensor time.
Timeline
October 1, 2026: Real-world evidence findings were presented at the EASD Annual Meeting.
Health Landscape
The push for closed-loop, automated insulin delivery represents a major shift toward systems that reduce the manual burden of diabetes management. Presenting these findings at the EASD Annual Meeting highlights the increasing reliance on real-world evidence to confirm the efficacy of these systems.
These findings illustrate how automated insulin systems can function outside of clinical settings, providing a metric for stability that you can use to frame questions for your endocrinologist. If you are considering transitioning to a patch pump or closed-loop system, discuss how these device performance metrics compare to your current glucose control goals.
The takeaway
Real-world data shows that automated insulin systems can provide stable glucose control for a large population of adults. Consider tracking your own time-in-range metrics alongside your physician to see if your current diabetes management tools are meeting these performance standards.
Further reading
For broader context on managing insulin delivery, visit the Diabetes section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe automated health monitoring technology improves daily life for patients with chronic conditions?
